Hologic stock gains as merger terms value shares near 52-week high

Published on 09/10/2026 at 12:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Hologic stock is being valued at USD 76.00 per share plus stock in the ongoing merger process as of September 10, 2026. The implied valuation comes close to the recent 52-week high and highlights the premium baked into the deal terms.

Fotorealistisches Mammographiegerät in hellem klinischem Untersuchungsraum mit Pflegekraft — Hologic zeigt ein Mammographie Gerät in einem modernen klinischen Untersuchungsraum ISIN US4364401012, Illustration mit AI erstellt.

Hologic stock (ISIN US4364401012) is currently valued at USD 76.00 per share in cash plus additional stock under the merger terms, as documented on September 10, 2026, giving investors a premium near the stock’s recent 52-week high.

Merger terms set cash and stock consideration

According to Robinhood on September 10, 2026, Hologic performed a cash and stock merger in which shareholders receive USD 76.00 in cash and 1.0000 share of the post-merger HOLX^ security for each existing Hologic share.

The USD 76.00 cash element is particularly relevant for investors because it represents a concrete anchor for valuation that can be compared with recent trading levels and the 52-week range quoted on major stock portals as of September 9, 2026.

Stock trades near the top of its 52-week range

Per data from MarketBeat as of September 9, 2026, Hologic stock on Nasdaq traded in a 52-week range between USD 51.90 and USD 76.07, with the upper end of that range closely aligned with the USD 76.00 cash component embedded in the merger termsMarketBeat.

On the same source snapshot, Hologic’s market capitalization stood at USD 16.97 billion as of September 9, 2026, with the shares trading around the USD 76.00 level, underscoring how the merger terms effectively value the company close to its recent highsMarketBeat.

Recent price action and 52-week high signal strong demand

Stocktwits reported that Hologic shares touched a fresh 52-week high alongside other names in its peer group, highlighting strong demand and momentum in the stock in early September 2026Stocktwits.

For investors, the fact that the cash leg of the merger consideration at USD 76.00 sits almost exactly at the recent 52-week high of USD 76.07 means the deal is being struck at a level that reflects the market’s strong view on Hologic’s prospects as of early September 2026, rather than at a discount to prior trading rangesMarketBeat.

Fundamental backdrop: earnings calendar and valuation metrics

MarketBeat’s overview notes that Hologic’s last reported earnings fell on January 29, 2026, for its most recent quarterly release, within a fiscal year that ends on September 30, 2026MarketBeat.

In the same profile, Hologic’s annual sales are cited at approximately USD 4.10 billion, providing a basis for investors to compare the USD 16.97 billion market capitalization implied at recent prices with underlying revenue, corresponding to a price-to-sales multiple around 4.14 as of September 9, 2026MarketBeat.

MarketBeat also lists Hologic’s net margin at 16.08 percent and return on equity at 19.58 percent, suggesting that the company is converting its healthcare equipment and supplies revenue into solid profitability and returns on capital in its most recent reporting yearMarketBeat.

Analyst consensus and price target context

According to the same MarketBeat consensus overview, analysts currently assign Hologic stock an average price target of USD 79.13, with the high estimate at USD 90.00 and the low at USD 76.00 as of September 9, 2026MarketBeat.

With the USD 76.00 cash component of the merger consideration matching the low end of the analyst target range and sitting only about 4.1 percent below the USD 79.13 average price target, the implied valuation is broadly aligned with Wall Street expectations rather than deeply below themMarketBeat.

Risks and considerations for shareholders

For existing shareholders, one consideration is that the merger structure uses both cash and stock, meaning future performance of the post-merger HOLX^ security will help determine the ultimate value realized above the base USD 76.00 cash level described in the corporate actions trackerRobinhood.

Investors also need to weigh general healthcare sector dynamics, including regulatory developments and reimbursement trends that can affect demand for Hologic’s diagnostic and surgical products, against the relatively high valuation multiples and near-peak price levels implied by the merger terms and the recent 52-week high noted in external market dataMarketBeat.

Hologic stock valuation from a retail investor perspective

For retail investors looking at Hologic stock as of September 10, 2026, the key numbers are the USD 76.00 cash per share in the merger consideration, the recent 52-week high of USD 76.07, and the analyst consensus price target of USD 79.13, all of which cluster in a relatively tight band around the mid-70 to high-70 USD levelRobinhood MarketBeat.

This alignment between merger terms, recent trading highs and consensus estimates suggests that the deal has been framed around the market’s prevailing view of Hologic’s worth and reduces the gap between fundamental valuation and transaction pricing that sometimes emerges in corporate actions.